Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The clinical symptoms of non transfusion dependent non severe aplastic anemia (NSAA) are
often lighter than that of severe aplastic anemia. Clinical observation is often used and the
treatment should be given according to the follow-up results of peripheral blood routine and
the survival condition of the patients. In recent years, a number of studies at home or
abroad have tended to intervene earlier. The risk of observation and waiting for disease
progression is higher. Early immunosuppression should be considered. For the treatment of non
transfusion dependent non severe aplastic anemia, the commonly used treatment regimen is
androgen combined with CSA. But the investigators find that Levamisole hydrochloride (LMS) as
a commonly used immunomodulatory drugs may be helpful to improving immune disorder symptoms
in NSAA patients. Therefore,the investigators are conducting a prospective, randomized
controlled study to compare the rate, side effects and long-term survival in non transfusion
dependent patients with NSAA between the androgen+CSA group and the androgen+CSA+LMS group.